Incorporation of an 125I-labeled hexa-iodinated diglyceride analog into low-density lipoprotein and high specific uptake by cells of cervical carcinoma cell lines

Radiation Research

Volumn 152, Issue 3, 1999, Pages 250-256

  Xiao, W ^a   Wang, L ^a   Ryan, J M ^a   H, Liu ^a,b  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^b MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 DIHYDROXYPROPAN 2 ONE 1,3 DIIOPANOATE; DIACYLGLYCEROL DERIVATIVE; IODINE 125; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; UNCLASSIFIED DRUG; 1,3-DIHYDROXYPROPAN-2-ONE 1,3-DIIOPANOATE; DIAGNOSTIC AGENT; DRUG CARRIER; DRUG DERIVATIVE; IOPANOIC ACID; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT;

ARTICLE; BINDING AFFINITY; DISSOCIATION CONSTANT; ENDOCYTOSIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; UTERINE CERVIX CARCINOMA; BINDING SITE; CARCINOMA; CELL CULTURE; CHEMISTRY; FEMALE; HELA CELL; KINETICS; METABOLISM; SCINTISCANNING; SYNTHESIS; UTERINE CERVIX TUMOR;

BINDING SITES; CARCINOMA; DRUG CARRIERS; FEMALE; HELA CELLS; HUMANS; IODINE RADIOISOTOPES; IOPANOIC ACID; KINETICS; LIPOPROTEINS, LDL; RADIOPHARMACEUTICALS; TUMOR CELLS, CULTURED; UTERINE CERVICAL NEOPLASMS;

EID: 0032588316     PISSN: 00337587     EISSN: None     Source Type: Journal    
DOI: 10.2307/3580324     Document Type: Article

References (42)

1. M. S. Brown and J. L. Goldstein, A receptor-mediated pathway for cholesterol homeostasis. Science 232, 34-47 (1986).
2. Y. K. Ho, G. S. Smith, M. S. Brown and J. L. Goldstein, Low density lipoprotein (LDL) receptor activity in human myelogenous leukemia cells. Blood 52, 1099-1104 (1978).
3. D. Gal, M. Ottashi, P. C. MacDonald, H. J. Buschbaum and E. R. Simpson, Low density lipoprotein as a potential vehicle for chemotherapeutic agents and radionucleotides in the management of gynecologic neoplasms. Am. J. Obstet. Gynecol. 139, 877-885 (1981).
4. S. Vitols, G. Gahrton, M. Bjorkholm and C. O. Peterson, Hypocholesterolemia in malignancy due to elevated LDL receptor activity in tumor cells: Evidence from studies in leukemic patients. Lancet II, 1150-1154 (1985).
5. M. J. Rudling, L. Stihle, C. O. Peterson and L. Skoog, Content of low density lipoprotein receptors in breast cancer tissue related to survival of patients. Br. Med. J. 292, 580-582 (1986).
6. M. J. Rudling, B. Angelin, C. O. Peterson and V. P. Collins, Low density lipoprotein receptor activity in human intracranial tumors and its relation to the cholesterol requirement. Cancer Res. 50, 483-487 (1990).
7. D. Gal, P. S. MacDonald, J. C. Porter, J. W. Smith and E. R. Simpson, Effect of cell density and confluency on cholesterol metabolism in cancer cells in monolayer culture. Cancer Res. 41, 473-477 (1981).
8. M. Iwanik, K. V. Shaw, B. Ledwith, S. Yanovich and J. M. Shaw, Preparation and interaction of a low density lipoprotein:daunomycin complex with P388 leukemic cells. Cancer Res. 44, 1206-1215 (1984).
9. M. Masquelier, S. Vitols and C. O. Peterson, Low density lipoprotein as a carrier of antitumoral drugs: In vivo fate of drug-human low-density lipoprotein complexes in mice. Cancer Res. 46, 3842-3847 (1986).
10. B. Lundberg, Preparation of drug-low density lipoprotein complexes for delivery of antitumoral drugs via the low density lipoprotein pathway. Cancer Res. 47, 4105-4108 (1987).
11. S. Vitols, K. Soderberg-Reid, M. Masquelier, B. Sjostrom and C. O. Peterson, Low density lipoprotein for delivery of a water insoluble alkylating agent to malignant cells. In vitro and in vivo studies of drug-lipoprotein complex. Br. J. Cancer 62, 724-729 (1990).
12. M. Samadi-Baboli, G. Favre, J. Bernadou, D. Berg and G. Soula, Comparative study of the incorporation of ellipticine-esters into low density lipoprotein (LDL) and selective cell uptake of drug-LDL complex via the LDL receptor pathway in vitro. Biochem. Pharmacol. 2, 203-212 (1990).
13. R. A. Firestone, Low-density lipoprotein as a vehicle for targeting antitumor compounds to cancer cells. Bioconjug. Chem. 5, 105-113 (1994).
14. P. de Smidt and T. J. C. van Berkel, Prolonged serum half-life of antineoplastic drugs by incorporation into the low density lipoprotein. Cancer Res. 50, 7476-7482 (1990).
15. S. Vitols, C. Peterson, O. Larsson, P. Holm and B. Aberg, Elevated uptake of low density lipoproteins by human lung cancer tissue in vivo. Cancer Res. 52, 6244-6247 (1992).
16. 99m-Tc-labeled LDL in B16-melanoma-bearing mice: Visualization of a preferential uptake by the tumor. Int. J. Cancer 54, 411-417 (1993).
17. 99mTc-low-density lipoprotein in human malignant glioma. Br. J. Cancer 71, 383-387 (1995).
18. R. C. Pittman and D. Steinberg, A new approach for assessing cumulative lysosomal degradation of proteins and other macromolecules. Biochem. Biophys. Res. Commun. 81, 1254-1259 (1978).
19. F. Jasanada, P. Urizzi, J. P. Souchard, F. Le Gaillard, G. Favre and F. Nepveu, Indium-111 labeling of low density lipoproteins with the DTPA-bis(stearylamide): Evaluation as a potential radiopharmaceutical for tumor localization. Bioconjug, Chem. 7, 72-81 (1996).
20. P. Urizzi, J. P. Souchard, C. Palevody, G. Ratovo, E. Hollande and F. Nepveu, Internalization of indium-labeled LDL through a lipid chelating anchor in human pancreatic-cancer cells as a potential radiopharmaceutical for tumor localization. Int. J. Cancer 70, 315-322 (1997).
21. M. A. Longino, J. P. Weichert, S. W. Schwendner, S. M. Szabo, R. E. Counsell and G. M. Glazer, Biodistribution of a new lipid-soluble CT contrast agent. Evaluation of cholesteryl iopanoate in the rabbit. Invest. Radiol. 18, 275-278 (1983).
22. J. P. Weichert, M. P. Groziak, M. A. Longino, S. W. Schwendner and R. E. Counsell, Potential tumor or organ-imaging agents. 27 Polyiodinated 1,3-disubstituted and 1,2,3-trisubstituted triacylglycerols. J. Med. Chem. 29, 2457-2465 (1986).
23. M. R. DeGalan, S. W. Schwendner, R. W. S. Skinner, M. A. Longino, M. Gross and R. E. Counsell, Iodine-125 cholesteryl iopanoate for measuring extent of atherosclerosis in rabbits. J. Nucl. Med. 29, 503-508 (1988).
24. V. N. Schumaker and D. L. Puppione, Sequential flotation ultracentrifugation. Meth. Enzymol. 128, 155-171 (1986).
25. S. K. Basu, J. L. Goldstein, R. G. W Anderson and M. S. Brown, Degradation of cationized low density lipoprotein and regulation of cholesterol metabolism in homozygous familial hypercholesterolemic fibroblasts. Proc. Natl. Acad. Sci. USA 73, 3178-3182 (1976).
26. A. Kader, P. J. Davis, M. Kara and H. Liu, Drug targeting using low density lipoprotein (LDL): physicochemical factors affecting drug loading into LDL particles. J. Controlled Release 55, 231-243 (1998).
27. J. L. Goldstein and M. S. Brown, Binding and degradation of low density lipoproteins to cultured human fibroblasts. J. Biol. Chem. 249, 5153-5162 (1974).
28. M. M. Bradford, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal. Biochem. 72, 248 (1976).
29. W. Xiao, L. Wang, P. J. Davis and H. Liu, Seal oil markedly enhances the transfer of a hydrophobic radiopharmaceutical into acetylated low density lipoprolein. Lipids, in press.
30. S. Lestavel-Delattre, F. Martin-Nizard, V. Clavey, P. Testard, G. Favre, G. Doualin, H. S. Houssaini, J. Bard, P. Duriez and J. Fruchart, Low-density lipoprotein for delivery of an acrylophenone antineoplastic molecule into malignant cells. Cancer Res. 52, 3629-3635 (1992).
31. J. L. Goldstein, Y. K. Ho, S. K. Basu and M. S. Brown, Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc. Natl. Acad Sci. USA 76, 333-337 (1979).
32. R. Gucalp, J. P. Dutcher and P. H. Wiernik, Overview by an oncologist: What are the imaging needs of the oncologist and oncological surgeon? Semin. Nucl. Med. 27, 3-9 (1997).
33. J. Carrasquillo, Imaging and dosimetry determinations using radio-labeled antibodies. Cancer Treat. Res. 68, 65-97 (1993).
34. D. D. Lasic, Doxorubicin in sterically stabilized liposomes. Nature 380, 561-562 (1996).
35. N. Emmanual, E. Kedar, E. M. Bolotin, N. I. Smorodinsky and Y. Berenholz, Targeted delivery of doxorubicin via sterically stabilized immunoliposomes: Pharmacokinetics and biodistribution in tumor bearing mice. Pharmacol. Res. 13, 861-868 (1996).
36. A. Mori and L. Huang, Targeted immunoliposomes: Potential role in the delivery of cytotoxic drugs. Clin. Immunother. 3, 227-240 (1995).
37. P. C. De Smidt and T. J. C. van Berkel, LDL-mediated drug targeting. Crit. Rev. Ther. Drug Carrier Syst. 7, 99-119 (1990).
38. J. M. Shaw, K. V Shaw, S. Yanovich, M. Iwanik, W. S. Futch, A. Rosowsky and L. B. Schook, Delivery of lipophilic drugs using lipoproteins. Ann. NY Acad. Sci. 507, 252-271 (1987).
39. D. Filipowska, T. Filipowski, B. Morelowska, W. Kazanowska, T. Laudanski, S. Lapinjoki, M. Akerland and A. Breeze, Treatment of cancer patients with a low density lipoprotein delivery vehicle containing a cytotoxic drug. Cancer Chemother. Pharmacol. 29, 396-400 (1992).
40. W. Xiao, L. Wang, T. M. Scott, R. E. Counsell and H. Liu, Radiolabeled cholesteryl iopanoate/acetylated low density lipoprotein as a potential probe for visualization of early atherosclerotic lesions in rabbits. Pharmacol. Res. 16, 420-426 (1999).
41. D. M. Parkin, P. Pisani and J. Ferlay, Estimates of the worldwide incidence of 25 major cancers in 1990. Int. J. Cancer 80, 827-841 (1999).
42. M. S. Brown and J. L. Goldstein, Receptor-mediated control of cholesterol metabolism. Science 191, 150-154 (1976).